Quantcast Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia - Congoo
 
 
WORLD Log In
Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia
Have an interest in this Story?
Sign Up for Real-Time email updates
Pharma Live  | November 05, 2009

SOUTH SAN FRANCISCO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. ( NASDAQ:SNSS) today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two P...
Read Full Article   
 
Leave a Comment: You must be logged in to leave a comment     Log in | Register
 

Featured Members
Mark Palmer Mark Palmer
Founder
Internet consultancies
David Hood David Hood
Director
Marketing/Public Relations

  
  View more profiles

 
Access dozens of premium and subscriptions sites Free! Download now.

Advertise   |   Build a News Circle   |   Get News Briefings   |   Congoo News Home   |   Get the Netpass
About Congoo   |   Terms   |   Privacy   |   Need Help?   |   Site Map
Copyright ©2009 Congoo.com. All Rights Reserved.